Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) and compare these long-term results to other bladder-preserving therapies in this population.

Now Viewing

EP: 1.Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC

EP: 2.SunRISe-1: Examining Combination Therapy for HR NMIBC

EP: 3.NURE-COMBO: Patient Population, Regimen, and Efficacy in MIBC

EP: 4.Novel Therapy + 5-Year Bladder Preservation for Patients with NMIBC

EP: 5.SunRISe-1 and NURE-COMBO: Addressing Unmet Needs and Expanding Treatment Options for Bladder Cancer

EP: 6.Novel Therapies for Bladder Cancer: Safety Profiles and Study Design Considerations

EP: 7.Final Insights on Current Bladder Cancer Clinical Trials

1) What are the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC)? How do these long-term results compare to other bladder-preserving therapies in this population?

Related Videos

Related Content

Advertisement

June 14th 2024

Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer

Laura Joszt, MA

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

June 14th 2024

Encouraging Data Emerge for Outpatient CAR T-Cell Treatment of Lymphoma

Christina Mattina

Results presented at the 2024 European Hematology Association Congress suggest that chimeric antigen receptor (CAR) T-cell therapy can be feasibly and safely delivered in the outpatient setting as treatment for lymphoma.

May 9th 2024

Frameworks for Advancing Health Equity: Urban Health Outreach

Giuliana Grossi

In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.

June 14th 2024

Dr Marta Rodríguez Martínez: Achieving a More Sustainable Research Model

Brooke McCormick

Marta Rodríguez Martínez, PhD, sustainability officer of the European Molecular Biology Laboratory, highlights the primary sources of scientific research waste and how to reduce them.

June 14th 2024

Cardiometabolic Interventions Focus on Accessibility, Evidence-Based Medicine

Giuliana Grossi

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.

Related Content

Advertisement

June 14th 2024

Tislelizumab Plus Chemo Meaningfully Improves OS, PFS in Advanced Esophageal Cancer

Laura Joszt, MA

The results of the 3-year follow-up show meaningful improvement in overall survival (OS) and progression-free survival (PFS) for tislelizumab plus chemotherapy compared with placebo plus chemotherapy.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

June 14th 2024

Encouraging Data Emerge for Outpatient CAR T-Cell Treatment of Lymphoma

Christina Mattina

Results presented at the 2024 European Hematology Association Congress suggest that chimeric antigen receptor (CAR) T-cell therapy can be feasibly and safely delivered in the outpatient setting as treatment for lymphoma.

May 9th 2024

Frameworks for Advancing Health Equity: Urban Health Outreach

Giuliana Grossi

In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.

June 14th 2024

Dr Marta Rodríguez Martínez: Achieving a More Sustainable Research Model

Brooke McCormick

Marta Rodríguez Martínez, PhD, sustainability officer of the European Molecular Biology Laboratory, highlights the primary sources of scientific research waste and how to reduce them.

June 14th 2024

Cardiometabolic Interventions Focus on Accessibility, Evidence-Based Medicine

Giuliana Grossi

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care® and Sutter Health, experts illuminated the current state of cardiometabolic health care and offered a glimpse into the future.